STAT+: Pharmalittle: We’re reading about a Lilly obesity drug trial, statistics for an Alzheimer’s drug, and more

Eli Lilly's late-stage obesity drug trial showed weight loss comparable to bariatric surgery but with concerning discontinuation rates of 11% due to adverse events, nearly double competitors' rates. A statistical technique called quantile aggregation used in Alzheimer's drug analyses may be overstating relationships between amyloid levels and cognitive outcomes.